Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy

Although current anticancer immunotherapies using immune checkpoint inhibitors (ICIs) have been reported with a high clinical success rate, numerous patients still bear ‘cold’ tumors with insufficient T cell infiltration and low immunogenicity, responding poorly to ICI therapy. Considering the advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qinjun, Sun, Tao, Jiang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006526/
https://www.ncbi.nlm.nih.gov/pubmed/34138315
http://dx.doi.org/10.1007/s40820-021-00622-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006526/
https://www.ncbi.nlm.nih.gov/pubmed/34138315
http://dx.doi.org/10.1007/s40820-021-00622-6

Ejemplares similares